In our study, we highlight ERK5 as a promising target for cancer therapies since ERK5 modulates not only the cancer cell viability but also the IL-6 production, which is involved in the regulation of type-1 immunity probably through the downregulation of IL-12p70 secretion from DCs (Fig. 7). This evidence concerns the gene IL6 and cancer.